According to an international study led by researchers from the Virginia Commonwealth University (VCU) School of Pharmacy, multiple genes contribute to risk for schizophrenia and appear to function in pathways related to transmission of signals in the brain and immunity [1]. The discovery provides scientists with a better understanding the molecular and biological mechanisms involved with schizophrenia that may improve disease management and identify new drug targets. The study is published in the April issue of JAMA Psychiatry.
Glioblastoma is the most common and aggressive type of brain cancer. Patients newly diagnosed with glioblastoma have a median survival of approximately one year with generally poor response to therapy [2]. Gene expression profiling studies suggest multiple subtypes of glioblastoma that, when fully defined, may allow for more personalized therapeutic approaches [3-4].
